- Home
- QSI vs RZLT Comparison
QSI vs RZLT Comparison
Compare QSI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- RZLT
- Stock Information
- Founded
- QSI 2013
- RZLT 2010
- Country
- QSI United States
- RZLT United States
- Employees
- QSI N/A
- RZLT N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- RZLT Health Care
- Exchange
- QSI Nasdaq
- RZLT Nasdaq
- Market Cap
- QSI 288.2M
- RZLT 283.3M
- IPO Year
- QSI N/A
- RZLT N/A
- Fundamental
- Price
- QSI $1.71
- RZLT $4.53
- Analyst Decision
- QSI Strong Buy
- RZLT Strong Buy
- Analyst Count
- QSI 3
- RZLT 8
- Target Price
- QSI $3.42
- RZLT $12.00
- AVG Volume (30 Days)
- QSI 10.1M
- RZLT 419.2K
- Earning Date
- QSI 03-03-2025
- RZLT 02-12-2025
- Dividend Yield
- QSI N/A
- RZLT N/A
- EPS Growth
- QSI N/A
- RZLT N/A
- EPS
- QSI N/A
- RZLT N/A
- Revenue
- QSI $2,266,000.00
- RZLT N/A
- Revenue This Year
- QSI $193.90
- RZLT N/A
- Revenue Next Year
- QSI $173.18
- RZLT N/A
- P/E Ratio
- QSI N/A
- RZLT N/A
- Revenue Growth
- QSI 232.26
- RZLT N/A
- 52 Week Low
- QSI $0.61
- RZLT $1.57
- 52 Week High
- QSI $5.77
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- QSI 39.90
- RZLT 41.29
- Support Level
- QSI $1.82
- RZLT $4.50
- Resistance Level
- QSI $2.10
- RZLT $5.28
- Average True Range (ATR)
- QSI 0.17
- RZLT 0.36
- MACD
- QSI -0.02
- RZLT -0.06
- Stochastic Oscillator
- QSI -0.93
- RZLT 4.03
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.